Osteogenesis imperfecta: Current treatment options and future prospects

Treatments in Endocrinology

Volumn 5, Issue 4, 2006, Pages 229-242

  Devogelaer, Jean Pierre ^a   Coppin, Christine ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN TYPE 1; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ACUTE PHASE RESPONSE; BONE DENSITY; BONE NECROSIS; BONE PAIN; BONE REMODELING; BRONCHOSPASM; DRUG ABSORPTION; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; EPISCLERITIS; ESOPHAGITIS; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; INHERITANCE; LEUKOPENIA; ORTHOPEDIC SURGERY; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY DISTRESS; REVIEW; SCLERITIS; SYMPTOMATOLOGY; THROMBOPHLEBITIS; TREATMENT DURATION; UVEITIS; FRACTURES, BONE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; FRACTURES, BONE; HUMANS; OSTEOGENESIS IMPERFECTA;

EID: 33746766255     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605040-00004     Document Type: Review

References (91)

1. Sillence DO. Osteogenesis imperfecta: an expanding panorama of variants. Clin Orthop 1981; 159: 11-25
2. Byers PH. Brittle bones: fragile molecules: disorders of collagen gene structure and expression. Trends Genet 1990; 6: 293-300
3. Ward LM, Lalic L, Roughley PJ, et al. Thirty-three novel COL1 A1 and COL1 A2 mutations in patients with osteogenesis imperfecta types I-IV. Hum Mutat 2001; 17: 434-9
4. Database of human type I and type III collagen mutations [online]. Available from URL: http://www.le.ac.uk/genetics/collagen [Accessed 2006 Jul 18]
5. Dalgleish R. The human type I collagen mutation database. Nucleic Acids Res 1997; 25: 181-7
6. Dalgleish R. The human collagen mutation database. Nucleic Acids Res 1998; 26: 253-5
7. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101-16
8. Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15: 1650-8
9. Glorieux FH, Ward LM, Rauch F, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17: 30-8
10. Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002; 31: 12-8
11. Labuda M, Morissette J, Ward LM, et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002; 31: 19-25
12. Byers PH, Steiner RD. Osteogenesis imperfecta. Annu Rev Med 1992; 43: 269-82
13. Roughley PJ, Rauch F, Glorieux FH. Osteogenesis imperfecta: clinical and molecular diversity. Eur Cell Mater 2003; 5: 41-7
14. Pierog SH, Fontana VJ, Ferrara A. Osteogenesis imperfecta: therapeutic challenge. N Y State J Med 1969; 69: 310-3
15. Zanzi I, Wallach S, Ellis KJ, et al. Long-term treatment of osteogenesis imperfecta tarda in adults with salmon calcitonin and calcium. Curr Ther Res Clin Exp 1976; 19: 189-97
16. Hoekman K, Papapoulos SE, Peters ACB, et al. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 1985; 61: 952-6
17. Baron R, Gertner JM, Lang R, et al. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983; 17: 204-7
18. Devogelaer JP, Malghem J, Maldague B, et al. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987; 16: 360-3
19. Jones SJ, Glorieux FH, Travers R, et al. The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: a survey using backscattered electron imaging. Calcif Tissue Int 1999; 64: 8-17
20. Rauch F, Travers R, Parfitt AM, et al. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000; 26: 581-9
21. Boyde A, Travers R, Glorieux FH, et al. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int 1999; 64: 185-90
22. Boivin G, Chavassieux P, Forin V, et al. Effects of pamidronate on bone modeling, bone remodeling and degree of mineralization of bone from children with osteogenesis imperfecta [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S24
23. Rauch F, Land C, Cornibert S, et al. High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Bone 2005; 37: 634-41
24. Bonjour J-PH, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73: 555-63
25. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75: 1060-5
26. Eastell R, Adams JE, Ahmed SF, et al. A practical guide to bone densitometry in children. Bath: National Osteoporosis Society, 2004 Nov
27. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000; 11: 281-4
28. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999; 9 Suppl. 2: S66-80
29. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-9
30. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38 (5): 617-27
31. Devogelaer J-P. New uses of bisphosphonates: osteogenesis imperfecta. Curr Opin Pharmacol 2002; 2: 748-53
32. Engelbert RH, Pruijs HE, Beemer FA, et al. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil 1998; 79: 1590-4
33. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-52
34. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846-50
35. Rauch F, Plotkin H, Travers R, et al. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Endocrinol Metab 2003; 88: 986-92
36. Rauch F, Plotkin H, Zeitlin L, et al. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18: 610-4
37. Falk MJ, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111: 573-8
38. DiMeglio LA, Ford L, McClintock C, et al. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004; 35: 1038-45
39. Zeitlin L, Rauch F, Travers R, et al. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. Bone 2006; 38: 13-20
40. Montpetit K, Plotkin H, Rauch F, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003; 111: 601-3
41. Arikoski P, Silverwood B, Tillmann V, et al. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy x-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004; 34: 539-4
42. Munns CFJ, Rauch F, Travers R, et al. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005; 20: 1235-43
43. Rauch F, Travers R, Plotkin H, et al. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110: 1293-9
44. van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 1992; 184: 249-54
45. Devogelaer JP, Nagant de Deuxchaisnes C. Use of pamidronate in chronic and acute bone loss conditions. Medicina 1997; 57 Suppl. 1: 101-8
46. Devogelaer JP, Nagant de Deuxchaisnes C, Malghem J, et al. Cyclical intermittent therapy with APD in a child with osteogenesis imperfecta: a 3-year follow-up of 7 cycles: evidence of fading away of the oldest radio-opaque metaphyseal bands. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Aalborg: Handelstrykkeriet Aalborg ApS, 1990: 1515-7
47. Rauch F, Travers R, Munns C, et al. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 2004; 19: 1191-3
48. Fuchs RK, Peacock M, McClintock C, et al. Children with osteogenesis imperfecta treated with bisphosphonates have site-specific bone responses to therapy [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S302
49. DiMeglio LA, Ford L, McClintock C, et al. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005; 18: 43-53
50. Glorieux FH, Plotkin H, Chiodo III J, et al. A randomized, open-label, comparison of zoledronic acid and pamidronate treatment in children with severe osteogenesis imperfecta [abstract]. Bone 2005; 36 Suppl. 1: S81
51. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349: 457-63
52. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64-8
53. Astrom E, Soderhall S. Beneficial effects of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86: 356-64
54. Anton J, Ricart S, Ros J, et al. Cyclic pamidronate in children with osteogenesis imperfecta: review of a protocol of a single-day infusion twice a year [abstract]. Bone 2005; 36 Suppl. 1: S82
55. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622-5
56. Gatti D, Viapiana O, Lippolis I, et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res 2005; 20: 1323-6
57. Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003; 18: 126-30
58. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20: 758-63
59. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, et al. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 1997; 156: 792-4
60. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004; 363: 1427-31
61. Vyskocil V, Pikner R, Kutilek S. Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 2005; 72: 416-23
62. Ward LM, Glorieux FH, Rauch F, et al. A randomized placebo-controlled trial of oral alendronate children and adolescents with osteogenesis imperfecta [abstract]. Bone 2005; 36 Suppl. 1: S31
63. Chevrel G, Schott A-M, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 2006; 21: 300-6
64. Gensure RC, Ponnapakkam T. Treatment of osteogenesis imperfecta type I with weekly alendronate [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S175
65. Senthilnathan S, Walker E, Cousins R, et al. Pamidronate for infants with osteogenesis imperfecta: comparison of different doses [abstract]. Bone 2005; 36 Suppl. 1: S82
66. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with type III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20: 977-86
67. Land C, Rauch F, Montpetit K, et al. Effect of intravenous pamidronate therapy on functional ability and degree of ambulation in children with osteogenesis imperfecta [abstract]. Bone 2005; 36 Suppl. 1: S32
68. Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005; 90: 4051-6
69. Devogelaer JP, Depresseux G. Estimation from early changes of serum procollagen type 1 aminoterminal propeptide of the lumbar BMD gain after 2 years in children suffering from severe osteogenesis imperfecta [abstract]. Bone 2005; 36 Suppl. 1: S41
70. Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, et al. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995; 10: 956-62
71. Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997; 61: 386-92
72. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004; 19: 278-88
73. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320-2
74. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994; 118: 220-4
75. Ruguiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34
76. Munns CF, Rauch F, Mier RJ, et al. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004; 35: 231-4
77. Munns CFJ, Rauch F, Zeitlin L, et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004; 19: 1779-86
78. Rauch F, Land C, Munns C, et al. The effect of pamidronate discontinuation in children and adolescents with moderate to severe osteogenesis imperfecta [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S23
79. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006; 91: 511-6
80. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-31
81. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41
82. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-15
83. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-26
84. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353: 555-65
85. Antoniazzi F, Bertoldo F, Mottes M, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996; 129: 432-9
86. Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxy-terminal propeptide of type I procollagen. J Bone Miner Res 2003; 18: 237-43
87. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227-31
88. Niyibizi C, Wallach CJ, Mi Z, et al. Approaches for skeletal gene therapy. Crit Rev Eukaryot Gene Expr 2002; 12: 163-73
89. Chamberlain JR, Schwarze U, Wang P-R, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004; 303: 1198-201
90. Pochampally RR, Horwitz EM, Digirolamo CM, et al. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects. Gene Ther 2005; 12: 1119-25
91. Le Blanc K, Gotherstrom C, Ringden O, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005; 79: 1607-14